Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
technetium-99m hexamethylpropylene amine oxime
- Development stage
- Approved
- Lead developer
- GE Healthcare
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Gamma Emitters → Radiopharmaceuticals, Small Molecules
- Administration
- Intravenous
01
Overview
Technetium-99m hexamethylpropylene amine oxime (HMPAO), also known as technetium Tc‑99m exametazime, is a radiopharmaceutical diagnostic agent. It consists of the chelating agent exametazime (HMPAO) complexed with the radioisotope technetium‑99m. The compound is used primarily in nuclear medicine for scintigraphic imaging to detect altered regional cerebral perfusion, particularly in stroke and other cerebrovascular diseases. Additionally, it is used for labeling leukocytes to localize intra-abdominal infections and inflammatory bowel disease. The mechanism of action involves the lipophilic nature of HMPAO, which allows it to cross cell membranes and the blood-brain barrier; once inside cells, it binds to mitochondria and nuclei, enabling imaging of tissue perfusion or infection sites[2][4][6].
- Brand names
- CeretecDrax ExametazimeMedi-Exametazim
- Other names
- technetium (99mTc) exametazimeTc 99m-HMPAOTc99m-HMPAOTc-99m-HMPAOhexamethylpropyleneamine oxime
02
Targets
GSH (Glutathione)
Beyond the preview
Go deeper on technetium-99m hexamethylpropylene amine oxime.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on technetium-99m hexamethylpropylene amine oxime.